Taxus brings Boston $42million from first 10 days on US market
This article was originally published in Clinica
Executive Summary
Boston Scientific has reported US sales of its Taxus Express2 drug-eluting stent of $42m for the first 10 selling days after its launch. With the number of accounts the company is selling to ramping up rapidly, US Taxus revenues look like they will comfortably meet Boston's expectation of $52-75m for the 23 selling days to March 31.
You may also be interested in...
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.